肾内科

EphrinB2信号通路与肾损伤后毛细血管稀疏及纤维化有关

作者:Yujiro Kida, Nicholas Ieronimakis, Jeremy S. Duffield et al. 来源:JASN 日期:2013-03-15
导读

         

 

EphrinB2 Reverse Signaling Protects against Capillary Rarefaction and Fibrosis after Kidney Injury
 
 
 
Abstract
 
Microvascular disease, a characteristic of acute and chronic kidney diseases, leads to rarefaction of peritubular capillaries (PTCs), promoting secondary ischemic injury, which may be central to disease progression. Bidirectional signaling by EphB4 receptor and ephrinB2 ligand is critical for angiogenesis during murine development, suggesting that ephrinB2 reverse signaling may have a role in renal angiogenesis induced by injury or fibrosis. Here, we found that ephrinB2 reverse signaling is activated in the kidney only after injury. In mice lacking the PDZ intracellular signaling domain of ephrinB2 (ephrinB2 ΔV), angiogenesis was impaired and kidney injury led to increased PTC rarefaction and fibrosis. EphrinB2 ΔV primary kidney pericytes migrated more than wild-type pericytes and were less able to stabilize capillary tubes in three-dimensional culture and less able to stimulate synthesis of capillary basement membrane. EphrinB2 ΔV primary kidney microvascular endothelial cells migrated and proliferated less than wild-type microvascular endothelial cells in response to vascular endothelial growth factor A and showed less internalization and activation of vascular endothelial growth factor receptor-2. Taken together, these results suggest that PDZ domain-dependent ephrinB2 reverse signaling protects against PTC rarefaction by regulating angiogenesis and vascular stability during kidney injury. Furthermore, this signaling in kidney pericytes protects against pericyte-to-myofibroblast transition and myofibroblast activation, thereby limiting fibrogenesis.
 
 
 
 
http://jasn.asnjournals.org/content/early/2013/03/13/ASN.2012080871.abstract
分享:

相关文章

评论

我要跟帖
发表
回复 小鸭梨
发表

copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像

京ICP证120392号  京公网安备110105007198  京ICP备10215607号-1  (京)网药械信息备字(2022)第00160号
//站内统计 //百度统计 //谷歌统计 //站长统计
*我要反馈: 姓    名: 邮    箱:
Baidu
map